PL356667A1 - A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress - Google Patents

A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress

Info

Publication number
PL356667A1
PL356667A1 PL00356667A PL35666700A PL356667A1 PL 356667 A1 PL356667 A1 PL 356667A1 PL 00356667 A PL00356667 A PL 00356667A PL 35666700 A PL35666700 A PL 35666700A PL 356667 A1 PL356667 A1 PL 356667A1
Authority
PL
Poland
Prior art keywords
vitamin
preventing
combination
delivery system
oxidative stress
Prior art date
Application number
PL00356667A
Other languages
English (en)
Polish (pl)
Inventor
Bent Hojgaard
Henrik Enghusen Poulsen
Jukka Salonen
Original Assignee
Ferrosan A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrosan A/S filed Critical Ferrosan A/S
Publication of PL356667A1 publication Critical patent/PL356667A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL00356667A 1999-08-20 2000-08-18 A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress PL356667A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199901145 1999-08-20
PCT/DK2000/000459 WO2001013901A2 (en) 1999-08-20 2000-08-18 A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress

Publications (1)

Publication Number Publication Date
PL356667A1 true PL356667A1 (en) 2004-06-28

Family

ID=8101522

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00356667A PL356667A1 (en) 1999-08-20 2000-08-18 A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress

Country Status (8)

Country Link
EP (1) EP1210079A2 (de)
JP (1) JP2003507419A (de)
AR (1) AR025343A1 (de)
AU (1) AU6558900A (de)
NZ (1) NZ517833A (de)
PL (1) PL356667A1 (de)
RU (1) RU2309733C2 (de)
WO (1) WO2001013901A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078296A2 (en) * 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
MXPA04009412A (es) * 2002-03-28 2005-12-12 Oxis Int Inc Metodos neuroprotectores, composiciones y metodos para seleccion de los mismos.
JP4690305B2 (ja) * 2003-01-17 2011-06-01 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 抗増殖性質を有する化合物
PL1689381T3 (pl) * 2003-09-05 2010-07-30 Matthias Rath Kompozycja farmaceutyczna zawierająca m.in. witaminę C, magnez, wyciąg z zielonej herbaty do hamowania chorób sercowo-naczyniowych (proliferacji SMC)
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CA2794734C (en) 2010-03-30 2017-12-12 Phosphagenics Limited Transdermal delivery patch
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法
CN116600815A (zh) * 2020-09-17 2023-08-15 株式会社力森诺科 自噬激活剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122157A (en) * 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
DE3569080D1 (en) * 1984-08-30 1989-05-03 Rodisma Pharma Prod Gmbh Process for sustaining the release of vitamins c and e
RU2063750C1 (ru) * 1993-07-21 1996-07-20 Сергеев Александр Васильевич Состав, обладающий адаптогенным действием
JPH07227256A (ja) * 1993-12-24 1995-08-29 Takeda Chem Ind Ltd 経口液剤
IL109539A0 (en) * 1994-05-03 1994-08-26 Yissum Res Dev Co Substained-release pharmaceutical system for the delivery of antioxidants
US5560928A (en) * 1995-06-23 1996-10-01 Defelice; Stephen L. Nutritional and/or dietary composition and method of using the same
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IT1283478B1 (it) * 1996-07-22 1998-04-21 Roberto Valducci Composizioni per integrazione nutrizionale comprendenti vitamine idrosolubili a rilascio prolungato
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives

Also Published As

Publication number Publication date
WO2001013901A3 (en) 2001-09-07
EP1210079A2 (de) 2002-06-05
AU6558900A (en) 2001-03-19
JP2003507419A (ja) 2003-02-25
WO2001013901A2 (en) 2001-03-01
RU2309733C2 (ru) 2007-11-10
NZ517833A (en) 2004-01-30
AR025343A1 (es) 2002-11-20
RU2002107015A (ru) 2003-11-10

Similar Documents

Publication Publication Date Title
GB2338414B (en) Intravesical drug delivery system
AU6158001A (en) Drug/drug delivery systems for the prevention and treatment of vascular disease
HUP0104168A3 (en) Spray on bandage and drug delivery system
EP1100508B8 (de) Pharmazeutische kombination mit einer trizyclischen verbindung und mindestens einer von zolpidem, zopiclone und brotizolam, zur behandlung oder verhinderung von schlafstörungen
AU2879100A (en) Formulation and system for intra-oral delivery of pharmaceutical agents
IL127189A0 (en) Compositions methods and devices for the transdermal delivery of drugs
EP1231864A4 (de) Am gewebe befestigbarer medikamentenverabreichungskatheter und methode zu deren anwendung
ZA9810641B (en) Pharmaceutical hydrogel formulations and associated drug delivery devices and methods
GB9904629D0 (en) Oral drug delivery system
IL143087A0 (en) Drug delivery systems and methods
GB9601969D0 (en) A system for the delivery of drugs and therapeutic agents
AU2938100A (en) Transdermal drug delivery system and method
EP1036573A4 (de) Gerät zum verabreichen einer substanz durch die haut oder eine schleimhaut
MXPA02000598A (es) Oligomeros de procianidina los cuales inhiben las metaloproteinasas de matriz y un medicamento que contiene la composicion efectiva de los mismos.
IL127572A (en) Pharmaceutical composition and medicament for nasal administration
EP1087753A4 (de) Zielgerichtetes liposomales arzneistoffverabreichungssystem
LT96148A (en) Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction
IL211081A0 (en) Methods and devices for providing prolonged drug therapy
HUP0401913A3 (en) Medicine for preventing and treating bromhidrosis
HUP0203908A3 (en) Osmotic delivery system and method for delivery first of all of medicine
EP1173192A4 (de) Verfahren und zusammensetzungen für eine gezielte verabreichung von medikamenten
IL126671A0 (en) Drug preferably for inhibiting inflammation
HUP0200812A3 (en) Vitamin d analogues and their pharmaceutical use
HUP9903375A3 (en) Synergistic pharmaceutical compositions containing olanzapine and analgetic drugs
AU3312900A (en) Formulations for treatment of pain comprising vitamin b12 and phenylanine

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)